The discovery of cancer cell and immune cell interaction in the tumor microenvironment has generated much excitement. Immune cells play important roles in the initiation and progression of cancer. Immune evasion may lead to enhanced tumorigenesis, cancer progression, and treatment failure. In many cancer types, clinical decisions are can no longer solely based on histopathological criteria in view of the complexity of the tumor microenvironment. To systematically improve the prognostic of cancer patients, we need to translate the immune evasion evidence to clinical practice. We believe that only when the identified disease subtypes are well established with a clear predictive model in place, coupled with comprehensive molecular and immune characterization of patients’ samples, precision medicine can be optimized to reach its fullest potential in treating cancer. In this research topic, we aim to gather the latest development in the term of preclinical model development, biomarker discovery, and therapeutic strategies including novel drug delivery systems to overcome immune evasion in cancer.
In this research topic, we aim to update on the latest development in designing novel preclinical research models to address immune evasion in both solid and hematological cancer. We also aim to update the novel biomarkers, gene signature, and molecular pathways that drive immune evasion in cancer. Understanding the importance of the tumor microenvironment in the immune evasion of cancer, we also wish to update on the latest cross-talks between immune cells and cancer cells. Furthermore, we aim to update the latest single or combined therapeutic approach as well as novel drug delivery systems that can address immune evasion in cancer.
We welcome submissions of Original Research Articles, Systematic Review, Meta-analysis, Reviews, and Mini-reviews, including but not limited to the following subtopics:
• Design of novel preclinical cancer model (such as cell-based model, organoids, organ-in-chip, genetically engineered animal model, syngeneic animal model, or patient-derived model) that recapitulate the immune evasion in cancer patient
• Discovery of novel biomarkers in contributing to immune evasion in cancer.
• Identification of gene signatures or molecular pathways in driving immune evasion in cancer.
• Identification of the crosstalk between cancer cells and immune cells in the tumor microenvironment
• Discovery of novel small molecules, standardized herbal extract/multi herbal preparation, gene therapy, cell therapy, or radiation as a single or combination approach in addressing immune evasion in cancer.
• Novel drug delivery that addresses the challenges in targeting immune evasion in cancer.
Standardized herbal extract/multi-herbal preparation should be accompanied by robust chemical and botanical composition quantified by established standards.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
The discovery of cancer cell and immune cell interaction in the tumor microenvironment has generated much excitement. Immune cells play important roles in the initiation and progression of cancer. Immune evasion may lead to enhanced tumorigenesis, cancer progression, and treatment failure. In many cancer types, clinical decisions are can no longer solely based on histopathological criteria in view of the complexity of the tumor microenvironment. To systematically improve the prognostic of cancer patients, we need to translate the immune evasion evidence to clinical practice. We believe that only when the identified disease subtypes are well established with a clear predictive model in place, coupled with comprehensive molecular and immune characterization of patients’ samples, precision medicine can be optimized to reach its fullest potential in treating cancer. In this research topic, we aim to gather the latest development in the term of preclinical model development, biomarker discovery, and therapeutic strategies including novel drug delivery systems to overcome immune evasion in cancer.
In this research topic, we aim to update on the latest development in designing novel preclinical research models to address immune evasion in both solid and hematological cancer. We also aim to update the novel biomarkers, gene signature, and molecular pathways that drive immune evasion in cancer. Understanding the importance of the tumor microenvironment in the immune evasion of cancer, we also wish to update on the latest cross-talks between immune cells and cancer cells. Furthermore, we aim to update the latest single or combined therapeutic approach as well as novel drug delivery systems that can address immune evasion in cancer.
We welcome submissions of Original Research Articles, Systematic Review, Meta-analysis, Reviews, and Mini-reviews, including but not limited to the following subtopics:
• Design of novel preclinical cancer model (such as cell-based model, organoids, organ-in-chip, genetically engineered animal model, syngeneic animal model, or patient-derived model) that recapitulate the immune evasion in cancer patient
• Discovery of novel biomarkers in contributing to immune evasion in cancer.
• Identification of gene signatures or molecular pathways in driving immune evasion in cancer.
• Identification of the crosstalk between cancer cells and immune cells in the tumor microenvironment
• Discovery of novel small molecules, standardized herbal extract/multi herbal preparation, gene therapy, cell therapy, or radiation as a single or combination approach in addressing immune evasion in cancer.
• Novel drug delivery that addresses the challenges in targeting immune evasion in cancer.
Standardized herbal extract/multi-herbal preparation should be accompanied by robust chemical and botanical composition quantified by established standards.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.